SEC Info - Eli Lilly & Co. - ‘8-K’ for 3/17/23

SEC Info℠

Home

Help

Please Sign In

Eli Lilly & Co. – ‘8-K’ for 3/17/23

On: Friday, 3/17/23, at 4:05pm ET · For: 3/17/23 · Accession #: 59478-23-118 · File #: 1-06351

  As Of               Filer                 Filing    For·On·As Docs:Size

 3/17/23  Eli Lilly & Co.                   8-K:5       3/17/23   11:267K

Current Report — Form 8-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     50K 
 6: R1          Cover Page                                          HTML     72K 
 9: XML         IDEA XML File -- Filing Summary                      XML     11K 
 7: XML         XBRL Instance -- lly-20230317_htm                    XML     41K 
 8: EXCEL       IDEA Workbook of Financial Reports                  XLSX      9K 
 3: EX-101.DEF  XBRL Definitions -- lly-20230317_def                 XML     49K 
 4: EX-101.LAB  XBRL Labels -- lly-20230317_lab                      XML    114K 
 5: EX-101.PRE  XBRL Presentations -- lly-20230317_pre               XML     51K 
 2: EX-101.SCH  XBRL Schema -- lly-20230317                          XSD     17K 
10: JSON        XBRL Instance as JSON Data -- MetaLinks               17±    23K 
11: ZIP         XBRL Zipped Folder -- 0000059478-23-000118-xbrl      Zip     22K

‘8-K’ — Current Report

This is an HTML Document rendered as filed. [ Alternative Formats ]

iX: C: C:

lly-20230317

i 0000059478 i false00000594782023-03-172023-03-170000059478us-gaap:CommonClassAMember2023-03-172023-03-170000059478lly:A718NotesDueJune12025Member2023-03-172023-03-170000059478lly:A1.625NotesDueJune22026Member2023-03-172023-03-170000059478lly:A2.125NotesDueJune32030Member2023-03-172023-03-170000059478lly:A625Notesdue2031Member2023-03-172023-03-170000059478lly:A500NotesDue2033Member2023-03-172023-03-170000059478lly:A6.77NotesDueJanuary12036Member2023-03-172023-03-170000059478lly:A1625NotesDue2043Member2023-03-172023-03-170000059478lly:A1.700Notesdue2049Member2023-03-172023-03-170000059478lly:A1125NotesDue2051Member2023-03-172023-03-170000059478lly:A1375NotesDue2061Member2023-03-172023-03-17


			UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM i 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): i March 17, 2023

i ELI LILLY AND COMPANY

(Exact Name of Registrant as Specified in its Charter)

i Indiana

i 001-06351

i 35-0470950

(State or Other Jurisdiction
of Incorporation)

(Commission
File Number)

(I.R.S. Employer
Identification No.)

i Lilly Corporate Center

i Indianapolis,

i Indiana

i 46285

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including Area Code: ( i 317) i 276-2000

Not Applicable

(Former Name or Former Address, if Changed Since Last Report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):


i ☐						Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


i ☐						Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


i ☐						Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


i ☐						Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

i Common Stock (no par value)

i LLY

i New York Stock Exchange

i 7 1/8% Notes due 2025

i LLY25

i New York Stock Exchange

i 1.625% Notes due 2026

i LLY26

i New York Stock Exchange

i 2.125% Notes due 2030

i LLY30

i New York Stock Exchange

i 0.625% Notes due 2031

i LLY31

i New York Stock Exchange

i 0.500% Notes due 2033

i LLY33

i New York Stock Exchange

i 6.77% Notes due 2036

i LLY36

i New York Stock Exchange

i 1.625% Notes due 2043

i LLY43

i New York Stock Exchange

i 1.700% Notes due 2049

i LLY49A

i New York Stock Exchange

i 1.125% Notes due 2051

i LLY51

i New York Stock Exchange

i 1.375% Notes due 2061

i LLY61

i New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company i ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 17, 2023, Eli Lilly and Company (the “Company”) entered into a non-competition and non-solicitation agreement with Daniel Skovronsky (the “Agreement”). Consistent with the terms of the Company’s Form of Non-Compete Payment Agreement, Dr. Skovronsky has agreed not to engage in certain competitive activities or solicit anyone who has a business relationship with the Company during the period of his employment and for a period of up to 12 months following termination of employment. Dr. Skovronsky will be entitled to receive payment of up to $5 million (less applicable reductions by the Company and deductions required by law for the payment of wages) in the event that the Company seeks to enforce the terms of the Agreement. The foregoing description of the Agreement is qualified in its entirety by reference to the full text of the Form of Non-Compete Payment Agreement filed as Exhibit 10.5 to the Company’s Annual Report on Form 10-K for the calendar year ended December 31, 2022.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.



ELI LILLY AND COMPANY
(Registrant)

By:						/s/ *Eric Dozier*
Name:						Eric Dozier
Title:						Executive Vice President, Human Resources and Diversity
Date:						March 17, 2023

Dates Referenced Herein and Documents Incorporated by Reference

This ‘8-K’ Filing	Date	Other Filings

Filed on / For Period end:	3/17/23
	12/31/22	10-K, 5
		List all Filings

2 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/08/24  Eli Lilly & Co.                   424B2                  2:582K                                   Donnelley … Solutions/FA
 2/07/24  Eli Lilly & Co.                   424B2                  1:523K                                   Donnelley … Solutions/FA

↑Top

Filing Submission 0000059478-23-000118 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Eli Lilly & Co. – ‘8-K’ for 3/17/23

On: Friday, 3/17/23, at 4:05pm ET · For: 3/17/23 · Accession #: 59478-23-118 · File #: 1-06351

Previous ‘8-K’: ‘8-K’ on 2/24/23 for 2/23/23 · Next: ‘8-K’ on / for 4/27/23 · Latest: ‘8-K’ on 2/9/24 for 2/7/24 · 2 References: By: Eli Lilly & Co. – ‘424B2’ on 2/8/24 By: Eli Lilly & Co. – ‘424B2’ on 2/7/24

Current Report — Form 8-KFiling Table of Contents

‘8-K’ — Current Report

This is an HTML Document rendered as filed. [ Alternative Formats ]

Dates Referenced Herein and Documents Incorporated by Reference

2 Subsequent Filings that Reference this Filing

Previous ‘8-K’: ‘8-K’ on 2/24/23 for 2/23/23 · Next: ‘8-K’ on / for 4/27/23 · Latest: ‘8-K’ on 2/9/24 for 2/7/24 · 2 References:

Current Report — Form 8-K

Filing Table of Contents